Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Oncol.

Sec. Cancer Epidemiology and Prevention

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1631356

This article is part of the Research TopicEquity in Cancer Prevention and Early DetectionView all articles

Global burden and cross-national inequalities of tobacco-attributable cancers in adults aged 40 and above, 1990-2021: a population-based study

Provisionally accepted
  • Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China

The final, formatted version of the article will be published soon.

Background: Tobacco exposure substantially increases the global cancer burden; however, studies targeting specific subgroups are scarce. We aimed to investigate global burden trends of tobaccoattributable cancers among people aged ≥40 and the associated cross-national inequalities based on the sociodemographic index (SDI).Methods: We performed secondary analyses on data from the Global Burden of Disease (GBD) Study 2021. The global tobacco-attributable cancer burden was assessed by age-standardized (ASR)disability adjusted life years (DALYs) and deaths. The estimated annual percentage changes were used to illustrate temporal global and regional trends from 1990 to 2021. Decomposition analyses determined the impact of population growth, aging, and epidemiological changes on disease burden. The slope inequality index (SII) and concentration index (CI) were used to quantify cross-country inequalities in the tobacco-attributable cancer burden.Results: In 2021, global tobacco-attributable ASR-DALYs among people aged ≥40 were 1,687.49 per 100,000 people, a continuous decline since 1990, and ASR deaths were 72.36 per 100,000 people. By 2030, they are projected to fall to 1,464.68 and 64.59 per 100,000, respectively. Men exhibited higher DALYs and deaths than women (40.8 million DALYs, 1.7 million deaths). The most prominent tobacco exposure was smoking (ASR-DALY: 1,603.98/100000). Among the 16 cancers observed, tracheal, bronchial, and lung cancers had significantly higher ASR-DALYs and ASR-related deaths than other cancers. Population growth was the main cause of the tobaccoattributable cancer burden, followed by epidemiological changes. The highest ASR-DALYs and deaths were observed in the medium-high SDI regions and the lowest in the low SDI regions. Health inequality analyses showed that the DALYs SII declined from 2,654/100,000 in 1990 to 1,178/100,000 in 2021; however, the difference between high and low SDI countries narrowed significantly. The DALYs CI was 0.17 in 1990 and 2021, and the mortality CI increased from 0.17 to 0.18.Conclusions: The cancer burden attributable to tobacco use varied significantly according to sex, age, region, and SDI. The global tobacco-attributable cancer burden among people aged ≥40 has been declining since 1990, paralleling mitigated yet persistent cross-national inequalities. The study's findings could help to develop strategies for improving the prevention and treatment of cancers.

Keywords: tobacco exposure, Cancer burden, Global Burden of Disease (GBD) Study, crossnational inequalities, sociodemographic index (SDI), Disability Adjusted Life Years (DALYs), deaths

Received: 19 May 2025; Accepted: 08 Jul 2025.

Copyright: © 2025 Li, Li, Tang, Chen and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Chuanben Chen, Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China
Chaoxiong Huang, Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.